MinervaX

Description

MinervaX is developing a prophylactic Group B Streptococcal (GBS) vaccine, AlpN GBS, that works as a clinical-stage immunization product intended for use in pregnancy and by older adults to prevent GBS-related adverse outcomes.

MinervaX is located in the Copenhagen ecosystem.

Related

• Bavarian NordicBavarian Nordic researches, develops, and manufactures life-saving vaccines, maintains product and pipeline materials, and operates process…
• BBelynticBelyntic develops T-Fender vaccines that use self-adjuvant, self-aggregating synthetic long peptides, combined with AI-based prediction, to…
• ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…
• SpliceBioSpliceBio builds protein splicing–based genetic medicines and develops therapeutics for diseases caused by mutations in large genes,…
• BiograilBiograil develops proprietary BIONDD® technology for oral delivery of biologics, using it in preclinical pharmaceutical work to turn…
• FineHeartFineHeart develops FlowMaker as a therapy for advanced heart failure, creates clinical-stage cardiology technology, and leads an IPCEI…
• CFM PharmaCFM Pharma is a Dutch clinical-stage biotech developing VANADIS®, a platform for tissue protection and repair in acute injury, with…
• QvanteqQvanteq develops biofunctional surfaces that address clinical adverse effects in medical devices and vascular stents, using Qstent…
• HealxHealx builds AI-driven drug discovery and development tools and therapies for rare disease patients, applying AI across discovery,…